scholarly journals Carbon-Ion Radiotherapy for Bone and Soft Tissue Tumors; Analysis of 92 Patients at Gunma University Heavy Ion Medical Center (GHMC)

2019 ◽  
Vol 105 (1) ◽  
pp. E806-E807
Author(s):  
T. Kaminuma ◽  
M. Okamoto ◽  
H. Kiyohara ◽  
T. Yanagawa ◽  
K. Shibuya ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Medical Center ◽  
Heavy Ion ◽  
Soft Tissue Tumors ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

scholarly journals Predictive factors of acute skin reactions to carbon ion radiotherapy for the treatment of malignant bone and soft tissue tumors

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Yosuke Takakusagi ◽  
Jun-ichi Saitoh ◽  
Hiroki Kiyohara ◽  
Takahiro Oike ◽  
Shin-ei Noda ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Predictive Factors ◽  
Soft Tissue Tumors ◽  
Carbon Ion Radiotherapy ◽  
Skin Reactions ◽  
Carbon Ion ◽  
Acute Skin Reactions

scholarly journals 12　Clinical Results of Carbon Ion Radiotherapy for Bone and Soft Tissue Tumors

RADIOISOTOPES ◽  
2015 ◽  
Vol 64 (6) ◽  
pp. 427-431
Author(s):  
Hiroki KIYOHARA ◽  
Masahiko OKAMOTO ◽  
Naoko OKANO
Keyword(s):  
Soft Tissue ◽  
Clinical Results ◽  
Soft Tissue Tumors ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

scholarly journals Carbon Ion Radiotherapy at the Gunma University Heavy Ion Medical Center: New Facility Set-up

Cancers ◽  
2011 ◽  
Vol 3 (4) ◽  
pp. 4046-4060 ◽  
Author(s):  
Tatsuya Ohno ◽  
Tatsuaki Kanai ◽  
Satoru Yamada ◽  
Ken Yusa ◽  
Mutsumi Tashiro ◽  
...  
Keyword(s):  
Medical Center ◽  
Heavy Ion ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Set Up ◽  
New Facility

scholarly journals Carbon ion radiotherapy for recurrent calf myxoid liposarcoma: a case report

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110097
Author(s):  
Xiaojun Li ◽  
Yanshan Zhang ◽  
Yancheng Ye ◽  
Ying Qi ◽  
Chunlan Feng ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Myxoid Liposarcoma ◽  
Ion Beams ◽  
Carbon Ion Radiotherapy ◽  
Irradiation Damage ◽  
Radiation Dermatitis ◽  
Complete Disappearance ◽  
Carbon Ion ◽  
The Right

Liposarcoma (LPS) is the most common soft tissue sarcoma. Myxoid LPS (MLPS) is the second most common subtype of LPS and accounts for 25% to 50% of all LPSs. Like most other soft tissue sarcomas, the mainstay of treatment for LPS is inevitably surgery. Multidisciplinary approaches, including surgery, chemotherapy, and radiotherapy, have been successful in the treatment of LPS during the last three decades. Even so, recurrence of LPS remains challenging. Carbon ion beams produce increased energy deposition at the end of their range to form a Bragg peak while minimizing irradiation damage to surrounding tissues, which facilitates more precise dosage and localization than that achieved with photon beams. Furthermore, carbon ion beams have high relative biologic effectiveness. We herein describe a patient who developed recurrent MLPS in the right calf after two surgeries and underwent carbon ion radiotherapy (CIRT), achieving complete disappearance of the tumor. The patient developed Grade 1 radiation dermatitis 30 days after CIRT, but no other acute toxicities were observed. The tumor had completely disappeared by 120 days after CIRT, and the patient remained disease-free for 27 months after CIRT. The CARE guidelines were followed in the reporting of this case.

Outcome and Toxicity of Carbon Ion Radiotherapy for Axial Bone and Soft Tissue Sarcomas

2020 ◽  
Vol 40 (5) ◽  
pp. 2853-2859 ◽  
Author(s):  
FRANCESCO CUCCIA ◽  
MARIA ROSARIA FIORE ◽  
AMELIA BARCELLINI ◽  
ALBERTO IANNALFI ◽  
BARBARA VISCHIONI ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

scholarly journals Carbon Ion Radiotherapy for Patients with Extracranial Chordoma or Chondrosarcoma - Initial Experience from Shanghai Proton and Heavy Ion Center

2019 ◽  
Vol 10 (15) ◽  
pp. 3315-3322 ◽  
Author(s):  
Shuang Wu ◽  
Ping Li ◽  
Xin Cai ◽  
Zhengshan Hong ◽  
Zhan Yu ◽  
...  
Keyword(s):  
Heavy Ion ◽  
Carbon Ion Radiotherapy ◽  
Initial Experience ◽  
Carbon Ion

Efficacy and Safety of Carbon Ion Radiotherapy in Bone and Soft Tissue Sarcomas

2002 ◽  
Vol 20 (22) ◽  
pp. 4466-4471 ◽  
Author(s):  
Tadashi Kamada ◽  
Hirohiko Tsujii ◽  
Hiroshi Tsuji ◽  
Tsuyoshi Yanagi ◽  
Jun-etsu Mizoe ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Total Dose ◽  
Local Control ◽  
Dose Escalation ◽  
Soft Tissue Sarcomas ◽  
Carbon Ion Radiotherapy ◽  
Skin Reactions ◽  
Carbon Ion ◽  
Acute Skin Reactions

PURPOSE: To evaluate the tolerance for and effectiveness of carbon ion radiotherapy in patients with unresectable bone and soft tissue sarcomas. PATIENTS AND METHODS: We conducted a phase I/II dose escalation study of carbon ion radiotherapy. Fifty-seven patients with 64 sites of bone and soft tissue sarcomas not suited for resection received carbon ion radiotherapy. Tumors involved the spine or paraspinous soft tissues in 19 patients, pelvis in 32 patients, and extremities in six patients. The total dose ranged from 52.8 to 73.6 gray equivalent (GyE) and was administered in 16 fixed fractions over 4 weeks (3.3 to 4.6 GyE/fraction). The median tumor size was 559 cm3 (range, 20 to 2,290 cm3). The minimum follow-up was 18 months. RESULTS: Seven of 17 patients treated with the highest total dose of 73.6 GyE experienced Radiation Therapy Oncology Group grade 3 acute skin reactions. Dose escalation was then halted at this level. No other severe acute reactions (grade > 3) were observed in this series. The overall local control rates were 88% and 73% at 1 year and 3 years of follow-up, respectively. The median survival time was 31 months (range, 2 to 60 months), and the 1- and 3-year overall survival rates were 82% and 46%, respectively. CONCLUSION: Carbon ion radiotherapy seems to be a safe and effective modality in the management of bone and soft tissue sarcomas not eligible for surgical resection, providing good local control and offering a survival advantage without unacceptable morbidity.

scholarly journals Dose Escalated Carbon Ion Radiotherapy for Localized Prostate Cancer in Shanghai Proton and Heavy Ion Center: Toxicity and Efficacy Outcomes At Two Years.

2021 ◽  
Author(s):  
Ping Li ◽  
Zhengshan Hong ◽  
Yongqiang Li ◽  
Xiaomao Guo ◽  
Shen Fu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Late Toxicity ◽  
Heavy Ion ◽  
Carbon Ion Radiotherapy ◽  
Localized Prostate Cancer ◽  
Cancer Specific Survival ◽  
Free Survival ◽  
Carbon Ion ◽  
Spot Scanning

Abstract Purpose: The purpose of this study was to prospectively analyze the safety and feasibility of spot scanning carbon ion radiotherapy (CIRT) for patients with localized prostate cancer.Methods: 118 localized prostate cancer patients treated with spot scanning CIRT at Shanghai Proton and Heavy Ion Center (SPHIC) were enrolled in this dose escalated study. The dose was gradually increased from 59.2GyE to 65.6GyE in 16 fractions. The primary endpoint was the acute and late toxicities. Secondary endpoints were biochemical relapse free survival (bRFS), distant metastasis free survival (DMFS), prostate cancer-specific survival (PCSS), and overall survival (OS).Results: The median follow-up time was 30.2 months (4.8-62.7 months). Acute grade 1 and 2 genitourinary (GU) toxicities were 15.3% and 18.6%, while acute grade 1 and 2 gastrointestinal (GI) toxicities were 2.5% and 0%, respectively. Late grade 1 and 2 GU toxicities were 4.2% and 1.7%, respectively. No late GI toxicity were observed. There were no cases of severe acute or late toxicity (≥grade 3). The significant association was not found between the factors and the acute GU toxicities except for CTV volume (p=0.031) on multivariate analysis. The 2-year bRFS, DMFS, PCSS, OS were 100%, 100%, 100% and 98.8%, respectively.Conclusion: The 2 years’ outcomes are encouraging, providing additional and useful information on the feasibility and safety of spot scanning CIRT for prostate cancer. Long term follow-up and prospective multi-institutional data are warranted to reinforce the role of CIRT in the management of localized prostate cancer.Trial registration: Clinicaltrial, NCT02739659. Registered 15 April 2016

Sign in / Sign up

Export Citation Format

Share Document